A Phase II Randomised, Open-label Study of Gemcitabine/Carboplatin First-line Chemotherapy in Combination With or Without the Antisense Oligonucleotide Apatorsen (OGX-427) in Advanced Squamous Cell Lung Cancers
The ongoing Phase II trial investigates the efficacy of Apatorsen (OGX-427), an antisense oligonucleotide targeting Hsp27, in combination with standard chemotherapy (gemcitabine/carboplatin) for patients with advanced squamous cell lung cancer (NSCLC). Given the limited treatment options for this patient population, successful outcomes could position Apatorsen as a novel therapeutic option, potentially enhancing the effectiveness of existing chemotherapy regimens. The market for lung cancer treatments is substantial, with increasing demand for innovative therapies. Competitive analysis indicates that while several therapies are available, few specifically target Hsp27, suggesting a unique market position if clinical efficacy is demonstrated. Diligence should focus on the trial's recruitment status, safety profile, and competitive landscape, particularly regarding other emerging therapies targeting similar pathways.
Indication: Squamous Cell Lung Cancer
Modality: RNA therapy
Target: Hsp27 (Heat Shock Protein 27)
Sponsor: Queen Mary University of London
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 15, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Hsp27 (Heat Shock Protein 27)
View original source fields
Condition raw: Squamous Cell Lung Cancer
Condition normalized: Squamous Cell Lung Cancer
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: Hsp27 (Heat Shock Protein 27)
Target normalized: Hsp27 (Heat Shock Protein 27)